Cargando…
Antipsychotic Medication Influences the Discriminative Value of Acylethanolamides as Biomarkers of Substance Use Disorder
Plasma acylethanolamides (NAEs), including the endocannabinoid anandamide (AEA), have been proposed as circulating biomarkers of substance use disorders. However, the concentration of these lipid transmitters might be influenced by the use of drugs prescribed for either the treatment of addiction or...
Autores principales: | Herrera-Imbroda, Jesús, Flores-López, María, Requena-Ocaña, Nerea, Araos, Pedro, Ropero, Jessica, García-Marchena, Nuria, Bordallo, Antonio, Suarez, Juan, Pavón-Morón, Francisco Javier, Serrano, Antonia, Mayoral, Fermín, Rodríguez de Fonseca, Fernando |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253203/ https://www.ncbi.nlm.nih.gov/pubmed/37298321 http://dx.doi.org/10.3390/ijms24119371 |
Ejemplares similares
-
Antidepressant Medication Does Not Contribute to the Elevated Circulating Concentrations of Acylethanolamides Found in Substance Use Disorder Patients
por: Herrera-Imbroda, Jesús, et al.
Publicado: (2023) -
Plasma concentrations of granulocyte colony-stimulating factor (G-CSF) in patients with substance use disorders and comorbid major depressive disorder
por: Galván, Sandra Torres, et al.
Publicado: (2021) -
Plasma Concentrations of Neurofilament Light Chain Protein and Brain-Derived Neurotrophic Factor as Consistent Biomarkers of Cognitive Impairment in Alcohol Use Disorder
por: Requena-Ocaña, Nerea, et al.
Publicado: (2023) -
Plasma Lysophosphatidic Acid Concentrations in Sex Differences and Psychiatric Comorbidity in Patients with Cocaine Use Disorder
por: Requena-Ocaña, Nerea, et al.
Publicado: (2023) -
Vascular Endothelial Growth Factor as a Potential Biomarker of Neuroinflammation and Frontal Cognitive Impairment in Patients with Alcohol Use Disorder
por: Requena-Ocaña, Nerea, et al.
Publicado: (2022)